<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05792540</url>
  </required_header>
  <id_info>
    <org_study_id>4/2023</org_study_id>
    <nct_id>NCT05792540</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders</brief_title>
  <official_title>Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive disorder (MDD) is a significant cause of disability that affects&#xD;
      approximately 16% of the world's population and is associated with chronic inflammation.&#xD;
      Although the mechanisms of MDD have not yet been clearly elucidated, NLRP3 inflammasomes have&#xD;
      been implicated in the pathogenesis of depression.NLRP3 inflammasome is an intracellular&#xD;
      multiprotein complex that consists of nod-like receptor protein 3, an adaptor protein, and a&#xD;
      procaspase-1 precursor. It is well known that a variety of danger signals, such as&#xD;
      pathogen-associated molecular patterns and danger-associated molecular patterns can activate&#xD;
      NLRP3 inflammasome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 28, 2023</start_date>
  <completion_date type="Anticipated">March 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>• The primary endpoint is the change in Hamilton Rating Scale</measure>
    <time_frame>3 months</time_frame>
    <description>• The primary endpoint is the change in Hamilton Rating Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoint is estimated by changes in serum biomarkers.</measure>
    <time_frame>3 months</time_frame>
    <description>The secondary endpoint is estimated by changes in serum biomarkers such as F) Nuclear factor erythroid 2-related factor 2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group ( fluoxetine 20 mg, n =25 ) who will receive fluoxetine (20 mg) once daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive fluoxetine (20 mg) once daily plus dapagliflozin 10 mg once daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive fluoxetine (20 mg) once daily plus atorvastatin 80 mg once daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine 20 mg</intervention_name>
    <description>Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain</description>
    <arm_group_label>Atorvastatin group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Dapagliflozin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg Tab</intervention_name>
    <description>Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance</description>
    <arm_group_label>Dapagliflozin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80mg</intervention_name>
    <description>Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia</description>
    <arm_group_label>Atorvastatin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Age ≥ 18 years Both males and females will be included Negative pregnancy test and&#xD;
        effective contraception. Depressed patients for at least 2 months with a Hamilton rating&#xD;
        score of more than 18.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with bipolar I or bipolar II disorder&#xD;
&#xD;
          -  Patients with personality disorders&#xD;
&#xD;
          -  Patients with eating disorders&#xD;
&#xD;
          -  Patients with substance dependence or abuse&#xD;
&#xD;
          -  Patients with concurrent active medical conditions&#xD;
&#xD;
          -  Patients with a history of seizures&#xD;
&#xD;
          -  Patients with a history of receiving Electroconvulsive therapy (ECT)&#xD;
&#xD;
          -  Patients with inflammatory disorders&#xD;
&#xD;
          -  Patients with allergies or contraindications to the used medications&#xD;
&#xD;
          -  Patients with finally pregnant or lactating females&#xD;
&#xD;
          -  Diabetic or hyperlipidaemic patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mostafa Bahaa, PhD</last_name>
    <phone>0201025538337</phone>
    <email>mbahaa@horus.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine, Menoufia University</name>
      <address>
        <city>Tanta</city>
        <state>Shebeen El-Kom</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 19, 2023</study_first_submitted>
  <study_first_submitted_qc>March 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>April 10, 2023</last_update_submitted>
  <last_update_submitted_qc>April 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Mostafa Bahaa</investigator_full_name>
    <investigator_title>Teaching Assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

